Sun Pharma to acquire Russia's JSC Biosintez; shares up
“With this move, we plan to acquire the product portfolio and local manufacturing capability in Russia which would help in expanding our presence in Russia and serving Russia pharmaceutical market more effectively,” Sun Pharma said in a statement.
The deal will involve cost acquisition of approximately RUB 1526 million ($24 million).Photo: Reuters/ Danish Siddiqui
Sensex, Nifty rise on IT, Tech stocks rally; Infosys, Sun Pharma, Dish TV stocks gain
Opening Bell: Sensex, Nifty halt post-budget selloff; Yes Bank, Tata Steel, Coal India stocks gain
Sun Pharma, China Medical System Holdings enter into two license agreementsSun Pharmaceuticals on Wednesday said that it has entered into an agreement to acquire 85.1% of JSC Biosintez – a Russian pharma company.
“With this move, we plan to acquire the product portfolio and local manufacturing capability in Russia which would help in expanding our presence in Russia and serving Russia pharmaceutical market more effectively,” Sun Pharma said in a statement.
The deal will involve cost acquisition of approximately RUB 1526 million ($24 million). Sun Pharma will also assume a debt of about $ 36 million as a part of the transaction.
Shares of Sun Pharma was trading at Rs 693.60 per share on BSE, up Rs 4 or 0.56%.
Share to buy: Sun Pharma set to give 11 pct returns in one month, say experts
Where should you invest in June 2019? TCS to Sun Pharma - These 7 stocks are money magnets